Showing results (391-400 of 1,005) with videos related to
Sort By:
Pageof 101
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.Ejhaem|July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutationBaptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.Ejhaem|May 19, 2023
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemiaIan M Bouligny, Graeme Murray, Michael Doyel, et al.Ejhaem|May 19, 2023
Red blood cell alloantibodies in paediatric transfusion in sub-Saharan Africa: A new cohort and literature reviewMacoura Gadji, Guéda Cobar, Alioune Thiongane, et al.Ejhaem|May 19, 2023
Community-level socioeconomic distress is associated with nutritional status in adults with sickle cell anemiaSyeda Akila Ally, Jin Han, Ryan Sun, et al.Ejhaem|May 19, 2023
Erythroleukemia: ClassificationNathalie Cervera, Arnaud Guille, José Adélaïde, et al.Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.Ejhaem|May 19, 2023
SARS-CoV-2 infection results in upregulation of Plasminogen Activator Inhibitor-1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severityKevin H Toomer, Gloria F Gerber, Yifan Zhang, et al.Ejhaem|May 19, 2023
VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohortOlga Benítez Hidalgo, Maria Fernanda Martinez Garcia, Irene Corrrales Insa, et al.Pageof 101